SI-BONE, Inc. (SIBN)

SI-BONE's stock has shown positive movement over the past six months, with a 38.65% increase in both the 3-month and 6-month periods as of early January 2026. The share price increased by 48.50% between December 30, 2024, and December 26, 2025. Wall Street analysts generally rate SIBN as "Very Bullish" or "Strong Buy," with price targets ranging from $23.00 to $27.00. The company reported preliminary fourth-quarter 2025 worldwide revenue of approximately $56.2 million to $56.3 million, reflecting about 15% year-over-year growth. U.S. revenue for the same period was estimated at $53.3 million to $53.4 million, an increase of approximately 14%. The company also saw an 18% increase in active U.S. physicians using its solutions, reaching around 1,640. For the full fiscal year 2025, worldwide revenue is projected to be between $200.8 million and $200.9 million, marking a 20% year-over-year growth. Insider trading activity over the past six months has shown a trend of sales, with several executives selling shares.

Demand for SI-BONE's products and services exhibits some seasonality, with the first quarter typically being a period of higher cash usage. The demand for SI-BONE's procedures is considered less likely to be deferred due to the debilitating pain and physical disability experienced by patients, allowing the company to demonstrate sustained growth even during periods of economic stress. Historical data suggests a seasonal pattern with a "Buy Date of November 19 and a Sell Date of February 24" showing positive returns compared to the S&P 500.

SI-BONE, Inc. is a medical device company focused on musculoskeletal disorders of the sacropelvic anatomy, operating in the Healthcare sector, specifically the Medical Devices or Therapeutic Devices industry. The company develops and commercializes minimally invasive surgical implant systems, including the iFuse Implant System®, iFuse-3D, iFuse TORQ, iFuse Bedrock Granite Implant System, iFuse TORQ TNT, and iFuse INTRA implants.

SI-BONE, Inc. operates in the United States and internationally, with its global headquarters in Santa Clara, California. The company primarily markets its products through a direct sales force, supplemented by third-party sales agents and resellers.

While explicit information detailing SI-BONE's brand reputation is not readily available, the company's consistent revenue growth, positive analyst ratings, and expansion of its product portfolio suggest a generally favorable perception within its market. The company's leadership in minimally invasive SI joint solutions and its focus on product innovation contribute to its market standing.

SI-BONE, Inc. has a diverse ownership structure, with institutional investors holding a significant portion of the company's stock, ranging from approximately 65.68% to 91.75%. Major institutional owners include BlackRock, Inc., American Century Companies Inc, Brown Advisory Inc, Orbimed Advisors Llc, Vanguard Group Inc, Champlain Investment Partners, LLC, First Light Asset Management, LLC, and Nuveen, LLC. Individual and insider ownership accounts for a smaller percentage, with insiders holding around 2.78% to 4.93% of shares. Notable individual/insider shareholders include Skyline Venture Partners V LP and John Gordon Freund.